DERM on RheumNow Podcast (September 2025) Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE,

Tweet Author

Tweet Content

DERM on RheumNow Podcast (September 2025) Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE, vasculitis, HS and dermatology drugs use, efficacy and side effects and more. https://t.co/zZpheX1epS https://t.co/uOd9Gy0V2E

Links

DERM on RheumNow Podcast (September 2025) | RheumNow https://buff.ly/K5hZWQV

QD Clinic: Stick or twist (when not to change treatment Dr. Richard Conway, Dublin, discusses a case about when not to

Tweet Author

RheumNow

Tweet Content

QD Clinic: Stick or twist (when not to change treatment Dr. Richard Conway, Dublin, discusses a case about when not to change treatment, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/kUopZ1bpVi https://t.co/mt0tKcQzKQ

Links

QD Clinic: Stick or twist (when not to change treatment) | RheumNow https://buff.ly/yO0sNHW

Rheum to Breathe Journal Club

Assessing ILD in Rheumatology Janet Pope, MD, shares practical insights on how rheumatologists should assess ILD in the

Tweet Author

RheumNow

Tweet Content

Assessing ILD in Rheumatology Janet Pope, MD, shares practical insights on how rheumatologists should assess ILD in their patients. Sponsored By: Boehringer Ingelheim https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/aAuxbJBxBn

Links

ILD Treatment and Guidelines | RheumNow https://buff.ly/w9qmEr7

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly

Tweet Author

RheumNow

Tweet Content

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly 20 years ago for the treatment of patients with SSc-ILD, evaluating cyclophosphamide vs. placebo, there have been several other randomized studies to guide the https://t.co/Dh7XpP6qhF

Panel of IPF assoc 8 biomarkers (eotaxin, Flt-3L, IL-8, MDC, MCP-1, MMP-2/7/9) tested in 2 RA-ILD cohorts (n 164). IPF

Tweet Author

RheumNow

Tweet Content

Panel of IPF assoc 8 biomarkers (eotaxin, Flt-3L, IL-8, MDC, MCP-1, MMP-2/7/9) tested in 2 RA-ILD cohorts (n 164). IPF multibiomarker scores higher in RA-ILF vs RA alone. Highest quartile had ~2 fold incr risk of prevalent & incident ILD https://t.co/vYg9iB4EtH https://t.co/5ZZx6gg7A4

Links

Performance of an Idiopathic Pulmonary Fibrosis Derived Multibiomarker Panel fo… https://buff.ly/5XPhfbk

24 September 2025

ILD and ANCA: What to do?

Several cohort studies conducted in Asia, Europe and the Americas have evaluated the clinical significance of antineutrophil cytoplasmic antibodies (ANCA) when detected in patients with interstitial lung disease (ILD) as well as the types of ILD encountered in patients with microscopic polyangiitis (MPA) and their effect on the prognosis of MPA.

QD Clinic: ILD with Positive SSA and Rash

Big Fat FDA Pink Slip (9.19.2025) Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today

Tweet Author

RheumNow

Tweet Content

Big Fat FDA Pink Slip (9.19.2025) Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. https://t.co/Za39hxI8Qf https://t.co/yN4K9tOuTt

Links

Big Fat FDA Pink Slip (9.19.2025) | RheumNow https://buff.ly/wmFVqk2

Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 R

Tweet Author

RheumNow

Tweet Content

Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 RCTs, 1175 SLE pts show higher CCI scores predicts increased all-cause mortality (OR 3.92(95% CI: 2.74–5.60) https://t.co/LXfsGo9iJq https://t.co/eK31lnFrJk

Links

Integrating Multimorbidity Assessment into Rheumatology Care: Prognostic Role o… https://buff.ly/4XIkJT0

Topics

DERM on RheumNow Podcast (September 2025) Content curated for dermatologists and skin deep HCPs – on Psoriasis, CLE,

QD Clinic: Stick or twist (when not to change treatment Dr. Richard Conway, Dublin, discusses a case about when not to

Rheum to Breathe Journal Club

Assessing ILD in Rheumatology Janet Pope, MD, shares practical insights on how rheumatologists should assess ILD in the

Scleroderma-associated Interstitial Lung Disease Since the first placebo-controlled randomized trial published nearly

Panel of IPF assoc 8 biomarkers (eotaxin, Flt-3L, IL-8, MDC, MCP-1, MMP-2/7/9) tested in 2 RA-ILD cohorts (n 164). IPF

QD Clinic: ILD with Positive SSA and Rash

Big Fat FDA Pink Slip (9.19.2025) Dr. Jack Cush reviews the news and journal reports from this week on RheumNow. Today

Should we be "scoring" comorbidity to predict outcomes? SLE metanalysis looked at Charlson Comorbidity index (CCI). 3 R

Do you get our email newsletter?